id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-341284-jmqdnart	Panagopoulos, Periklis	Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection	2020-06-12		.txt	text/plain	1548	106	53	Further studies are needed in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection. 9 The aim of the present study was to assess the impact of lopinavir/ritonavir as a third agent for the treatment of SARS COV 2 infection especially for patients with severe pneumonia emphasizing in the number of days needed for reduction of viral load. However, the number of days needed for the first negative result of RT-PCR for SARS-CoV-2 was significantly lower for patients of group A. The present study suggests that lopinavir/ritonavir could be a potential effective choice in treatment of patients with CoVID-19. 12 However, a retrospective study conducted in China including 134 patients with CoVID-19 showed no effect on accelerating the clearance of SARS-CoV-2. Further studies are needed with larger patient series in order to evaluate the effectiveness of lopinavir/ritonavir in the treatment of patients with SARS-CoV-2 infection and confirm the findings of the present study.	./cache/cord-341284-jmqdnart.txt	./txt/cord-341284-jmqdnart.txt